You also may be interested in...
Policy
This memorandum provides guidance for a COVID-19 laboratory pre-testing questionnaire that will be mandatory for all Active Duty Service members and encouraged for all other DOD beneficiaries treated at military medical treatment facilities.
Policy
This DODI establishes policy, assigns responsibilities, and prescribes procedures for administering the DOD Privacy and Civil Liberties Programs.
Policy
This EO outlines who should receive priority access to COVID-19 vaccines developed in the United States or procured by the United States Government (“United States Government COVID-19 Vaccines”).
Policy
This memorandum provides guidance on the provision of coronavirus disease 2019 (COVID-19) vaccines. The Defense Health Agency (DHA) is the lead coordinating DOD Component for executing this guidance, in coordination with the Military Departments and other DOD Components.
Policy
Establishes the DHA's plan to return to full operations and support the whole-of-government response, during the Coronavirus Disease 2019 (COVID-19) pandemic
Policy
Establishes the DHA's procedures to set procedures, responsibilities, and implement guidance for administering the DHA RA Program in accordance with federal guidelines.
- Identification #: 1020.01
- Date: 11/2/2020
- Type: Administrative Instructions
- Topics:
Disability Evaluation
Policy
This PGI provides standard language that shall be included in all purchased and non-purchased care solicitations and contracts where the contractor’s performance involves access to PII/PHI (unless those solicitations and contracts incorporate the TRICARE Manuals in their entirety, in which case this PGI does not apply).
Policy
CMS Checklist for MTF Claims
- Identification #: N/A
- Date: 10/8/2020
- Type: Guidelines
- Topics:
N/A
Policy
In accordance with the authority in DOD Directive 5124.02, this issuance establishes policy, assigns responsibilities, and prescribes procedures regarding the standards for military service accession, retention, separation, in-service transition, and medical care for Service members and applicants for accession to the Military Services with gender dysphoria or who are transgender, as applicable.
Policy
The Department of Defense (DOD) Pharmacy and Therapeutics (P&T) Committee (henceforth, P&T Committee) is responsible for development and maintenance of the TRICARE Uniform Formulary. This charter outlines the roles and responsibilities of the DOD P&T Committee.
- Identification #: N/A
- Date: 8/31/2020
- Type: Guidelines
- Topics:
N/A
Policy
Implements instructions, assigns responsibilities, and prescribes procedures for the DOD Northern Hemisphere (NH) and Southern Hemisphere (SH) Seasonal influenza vaccination program.
Policy
Process for requesting immunization exemptions, pursuant to the Navy Military Personnel Manual.
Policy
The Defense Health Agency (DHA) Memorandum, based on the authority of References (a) and (b), and in accordance with the guidance of References (c) and (d), establishes the DHA’s procedures to standardize the coding for Coronavirus 2019 (COVID-19) Military Medical Treatment Facilities (MTFs). This memorandum cancels and replaces DHA- Policy Memorandum 20-003 of (13 April 2020). A change was issued since the cancelled Memorandum 20-003 of (13 April 2020), the Attachment titles were updated to reflect that Attachments 1, 2, and 4 are considered Policies as opposed to Guidance.
Showing results 46 - 60
Page 4 of 70
News Around the Military Health System
You are leaving Health.mil
The appearance of hyperlinks does not constitute endorsement by the Department of Defense of non-U.S. Government sites or the information, products, or services contained therein. Although the Defense Health Agency may or may not use these sites as additional distribution channels for Department of Defense information, it does not exercise editorial control over all of the information that you may find at these locations. Such links are provided consistent with the stated purpose of this website.
You are leaving Health.mil
View the external links disclaimer.
Last Updated: September 15, 2022